Whose cells are they? Public perceptions about owning autologous cells

To further public understanding of regenerative medicine, EuroStemCell has published lay summaries for all articles from the latest Regenerative Medicine special focus issue.

Go to the profile of Regenerative Medicine
Dec 05, 2017
0
0
Upvote 0 Comment

EuroStemCell have launched a digital platform to accompany the publication of the Regenerative Medicine two-part Special Focus Issue entitled “Regenerative Medicine in Society: Interdisciplinary Perspectives”. The platform presents lay summaries of each article in the issue which are freely available to all in order to engage and educate non-experts on the key issues surrounding regenerative medicine.

You can now read the lay summary for the article entitled, “Identity and ownership issues in the regulation of autologous cells” from Douglas Sipp [1].

The growing international industry of unproven stem cell therapies around the globe has increasingly focused on using autologous cells and promoted therapies as services that enable patients to access the medical potential of their own cells. Mr Sipp’s examination of a set of public comments submitted to the US Federal Drug Administration reveals strong public opinions about the ownership of autologous cells lying with the individual they come from. However, this appears to contradict current legal interpretations of ownership rights for unprocessed cellular materials, which may have to be revisited and revised to address these issues.

What questions & challenges are raised? What insight and direction does this give for research policies? To find out, read the full lay summary on the EuroStemCell website here: https://www.eurostemcell.org/regenerative-medicine-society/whose-cells-are-they-public-perceptions-about-owning-autologous-cells

The full original article can be accessed here: https://www.futuremedicine.com/doi/10.2217/rme-2017-0063

 

References

[1] Sipp D. Identity and ownership issues in the regulation of autologous cells. Regen. Med. 12(7), 827–838 (2017).

Go to the profile of Regenerative Medicine

Regenerative Medicine

Journal, Future Science Group

Regenerative Medicine is an award-winning peer-reviewed journal, in print and web formats. The journal provides a forum to address the important challenges and advances in stem cell research and regenerative medicine, delivering this essential information in concise, clear and attractive article formats. Among other indexing services Regenerative Medicine is listed by MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Emcare, Biological Abstracts, BIOSIS Previews, Biotechnology Citation Index®, Journal Citation Reports/Science Edition®, Scopus® with an Impact Factor of 2.786 (2014). Each issue contains expertly drafted Reviews, Original Research articles, Perspectives, Editorials, topical insight from international leaders in their field, and additional added-value content. The Senior Editor of the journal is Professor Chris Mason, University College London. You can find out more about Regenerative Medicine at our website (www.future-science-group.com/journalprofile/regenerative-medicine/), where you can find the aims and scope of the journal and details of our international editorial board.

No comments yet.